D
Britannia Life Sciences Inc. BLAB
CNSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

03/31/2025 12/31/2024 09/30/2024 06/30/2024 03/31/2024
Net Income -- -124.85% -262.22% -515.75% --
Total Depreciation and Amortization -- -21.00% -26.65% -23.41% --
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items -- 116.29% 280.65% 70.64% --
Change in Net Operating Assets -- -42.87% -26.25% -116.57% --
Cash from Operations -- 16.82% -84.78% -97.92% -28.55%
Capital Expenditure -- -91.49% -102.24% 99.01% --
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities -- -661.18% -263.04% -- --
Cash from Investing -- 89.47% -203.62% 78.84% -93.94%
Total Debt Issued -- -- -- -- --
Total Debt Repaid -- -19.31% -22.49% -13.71% --
Issuance of Common Stock -- -- -- -- --
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -- -- -- -- --
Cash from Financing -- -15.96% 140.23% -11.63% -123.51%
Foreign Exchange rate Adjustments -- -102.77% 140.31% -83.51% --
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash -- 101.59% 163.71% -243.88% -349.49%